The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia

MG Vilia, E Fonte, T Veliz Rodriguez, M Tocchetti, P Ranghetti, L Scarfò, N Papakonstantinou, S Ntoufa, K Stamatopoulos, P Ghia, M Muzio

Research output: Contribution to journalArticle

Abstract

Toll interleukin-1 receptor 8 (also known as TIR8, SIGIRR, or IL1R8) is a transmembrane receptor that inhibits inflammation. Accordingly, genetic inactivation of this protein exacerbates chronic inflammation and inflammation-associated tumors in mice. In particular, lack of TIR8 triggers leukemia progression in a mouse model of chronic lymphocytic leukemia (CLL), supporting its role as a novel tumor restrainer. The aim of this study was to measure the amount of TIR8 mRNA and protein in CLL cells, and to analyze its regulation of expression. Circulating leukemic cells expressed lower levels of TIR8 compared to normal B-lymphocytes. Treatment of CLL cells with Azacytidine restored higher levels of TIR8 suggesting that DNA methylation may be involved in modulating TIR8 expression, with implications for novel therapeutic strategies. © 2017 Informa UK Limited, trading as Taylor & Francis Group
Original languageEnglish
Pages (from-to)2419-2425
Number of pages7
JournalLeukemia and Lymphoma
Volume58
Issue number10
DOIs
Publication statusPublished - 2017

Fingerprint Dive into the research topics of 'The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

  • Cite this

    Vilia, MG., Fonte, E., Veliz Rodriguez, T., Tocchetti, M., Ranghetti, P., Scarfò, L., Papakonstantinou, N., Ntoufa, S., Stamatopoulos, K., Ghia, P., & Muzio, M. (2017). The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia. Leukemia and Lymphoma, 58(10), 2419-2425. https://doi.org/10.1080/10428194.2017.1295142